Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
37.23 USD | -0.98% | +15.95% | +92.11% |
06-03 | Neurogene's Gene Therapy For Rett Syndrome Picked For FDA Pilot Program | MT |
06-03 | Neurogene Inc. Announces NGN-401 Gene Therapy for Rett Syndrome Selected by FDA for Start Pilot Program | CI |
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
SubscribeEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+92.11% | 483M | |
+48.64% | 56.65B | |
-6.44% | 39.44B | |
+40.29% | 39.03B | |
-11.17% | 26.86B | |
+14.28% | 26.75B | |
-21.40% | 19.03B | |
+0.96% | 12.28B | |
+25.64% | 12.26B | |
+27.04% | 12.04B |
- Stock Market
- Equities
- NGNE Stock
- News Neurogene Inc.
- Transcript : Neoleukin Therapeutics, Inc., Q4 2021 Earnings Call, Mar 01, 2022